COMPUTATIONAL INVESTIGATION OF THE ANTICOAGULANT POTENTIAL OF SARGASSUM SP. BIOACTIVE COMPOUNDS
DOI:
https://doi.org/10.22159/ijap.2026v18i1.56715Keywords:
Anticoagulant, Bioactive compounds, Molecular dynamics, Network pharmacology, Sargassum spAbstract
Objective: This study investigates the anticoagulant potential of bioactive compounds from Sargassum sp. using computational techniques. The goal is to explore their ability to modulate thrombosis, coagulation, and inflammation-related pathways through molecular docking, network pharmacology, and molecular dynamics (MD) simulations.
Methods: Network pharmacology was applied to identify target proteins related to thrombosis and coagulation. Gene Ontology (GO) and KEGG enrichment analyses highlighted relevant biological functions. Molecular docking simulations assessed binding interactions between bioactive compounds and coagulation-related proteins, while molecular dynamics simulations evaluated the stability of these complexes.
Results: A total of 109 coagulation-related proteins were identified, with 35 core proteins forming a highly connected PPI network. Enriched pathways included platelet aggregation and endothelial function. Docking results showed stable binding of alginate and fucoxanthin to SRC and HSP90AA1, with binding scores of-4.7 and-4.3 kcal/mol, respectively. Fucoidan demonstrated stronger binding to MAPK1 (-2.6 kcal/mol). Molecular dynamics simulations confirmed stable complexes, but further simulations (100 ns) are recommended to refine the findings.
Conclusion: Sargassum compounds, particularly alginate and fucoxanthin, may modulate thrombosis and coagulation pathways, likely through indirect mechanisms like inflammation and platelet aggregation. Experimental validation is required to confirm these computational predictions. This study underscores the value of computational models in hypothesis generation and the need for experimental confirmation.
References
1. Cairns JA. Efficacy and limitations of warfarin and novel oral anticoagulants with atrial fibrillation. Left atrial appendage closure: mechanical approaches to stroke prevention in atrial fibrillation: Springer; 2016. p. 17-36.
2. Wang M, Zeraatkar D, Obeda M, Lee M, Garcia C, Nguyen L. Drug-drug interactions with warfarin: a systematic review and meta-analysis. Br J Clin Pharmacol. 2021;87(11):4051-100. doi: 10.1111/bcp.14833, PMID 33769581.
3. Tan J, Bae S, Segal JB, Zhu J, Alexander GC, Segev DL. Warfarin use and the risk of stroke, bleeding and mortality in older adults on dialysis with incident atrial fibrillation. Nephrology (Carlton). 2019;24(2):234-44. doi: 10.1111/nep.13207, PMID 29219209, PMCID PMC5993567.
4. Patriota YB, Chaves LL, Gocke EH, Severino P, Soares MF, Soares Sobrinho JL. Applied nanotechnologies in anticoagulant therapy: from anticoagulants to coagulation test performance of drug delivery systems. Appl Nano. 2021;2(2):98-117. doi: 10.3390/applnano2020009.
5. Shute JK. Heparin low molecular weight heparin and non-anticoagulant derivatives for the treatment of inflammatory lung disease. Pharmaceuticals (Basel, Switzerland). 2023;16(4):584. doi: 10.3390/ph16040584, PMID 37111341, PMCID PMC10141002.
6. Jackevicius CA, Lu L, Ghaznavi Z, Warner AL. Bleeding risk of direct oral anticoagulants in patients with heart failure and atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2021;14(2):e007230. doi: 10.1161/circoutcomes.120.007230, PMID 33541109.
7. Welander F, Renlund H, Dimeny E, Holmberg H, Sjalander A. Direct oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation and CKD G3-G5D. Clin Kidney J. 2023;16(5):835-44. doi: 10.1093/ckj/sfad004, PMID 37151425, PMCID PMC10157779.
8. Dwivedi R, Pomin VH. Marine antithrombotics. Mar Drugs. 2020;18(10):514. doi: 10.3390/md18100514, PMID 33066214, PMCID PMC7602030.
9. Jayawardena TU, Sanjeewa KK, Nagahawatta DP, Lee HG, Lu YA, Vaas AP. Anti-inflammatory effects of sulfated polysaccharide from Sargassum swartzii in macrophages via blocking TLR/NF-Κb signal transduction. Mar Drugs. 2020;18(12):601. doi: 10.3390/md18120601, PMID 33260666, PMCID PMC7760840.
10. Li Y, Zheng Y, Zhang Y, Yang Y, Wang P, Imre B. Brown algae carbohydrates: structures pharmaceutical properties and research challenges. Mar Drugs. 2021;19(11):620. doi: 10.3390/md19110620, PMID 34822491, PMCID PMC8623139.
11. Sanger G, Wonggo D, Montolalu L, Dotulong V. Pigments constituents phenolic content and antioxidant activity of brown seaweed Sargassum sp. IOP Conf S Earth Environ Sci. 2022;1033(1):012057. doi: 10.1088/1755-1315/1033/1/012057.
12. Pandian P, Srinivasan NJ. Anticoagulant properties of marine algae: a systematic review. JoRiPS. 2021;12(2):1529 38.
13. Saraswati GPE, Giriwono PE, Iskandriati D. Screening of in vitro anti-inflammatory and antioxidant activity of sargassum ilicifolium crude lipid extracts from different coastal areas in Indonesia. Mar Drugs. 2021;19(5):252. doi: 10.3390/md19050252, PMID 33925071, PMCID PMC8146618.
14. El Kalyoubi SA, Ragab A, Abu Ali OA, Ammar YA, Seadawy MG, Ahmed A. One-pot synthesis and molecular modeling studies of new bioactive spiro-oxindoles based on uracil derivatives as SARS-CoV-2 inhibitors targeting RNA polymerase and spike glycoprotein. Pharmaceuticals (Basel, Switzerland). 2022;15(3):376. doi: 10.3390/ph15030376, PMID 35337173, PMCID PMC8954694.
15. Gentile F, Agrawal V, Hsing M, Ban F, Norinder U, Gleave ME. Deep docking a deep learning approach for Virtual Screening of Big Chemical Datasets. bioRxiv. 2019:15.877316. doi: 10.1101/2019.12.15.877316.
16. Jia LY, Cao GY, Li J, Gan L, Li JX, Lan XY. Investigating the pharmacological mechanisms of SheXiang XinTongNing against coronary heart disease based on network pharmacology and experimental evaluation. Front Pharmacol. 2021;12:698981. doi: 10.3389/fphar.2021.698981, PMID 34335263, PMCID PMC8316858.
17. Wang Y, Yang SH, Zhong K, Jiang T, Zhang M, Kwan HY. Network pharmacology-based strategy for the investigation of the anti-obesity effects of an ethanolic extract of zanthoxylum bungeanum maxim. Front Pharmacol. 2020;11:572387. doi: 10.3389/fphar.2020.572387, PMID 33364948, PMCID PMC7751641.
18. Alotaibi NM, Alotaibi MO, Alshammari N, Adnan M, Patel M. Network pharmacology combined with molecular docking molecular dynamics and in vitro experimental validation reveals the therapeutic potential of thymus vulgaris L. essential oil (thyme oil) against human breast cancer. ACS Omega. 2023;8(50):48344-59. doi: 10.1021/acsomega.3c07782, PMID 38144096, PMCID PMC10734022.
19. Syahputra D, Ysrafil Y, Alexandra FD, Praja RK, Fatmaria F, Pratika RA. Network pharmacology combined with molecular docking and molecular dynamics to verify the therapeutic potential of mung beans (Vigna radiata) against prostate cancer. Beni-Suef Univ J Basic Appl Sci. 2024;13(1):100. doi: 10.1186/s43088-024-00552-3.
20. Nurhasanah N, Fadilah F, Bahtiar A. Prediction of active compounds of muntingia calabura as potential treatment for chronic obstructive pulmonary diseases by network pharmacology integrated with molecular docking. Int J App Pharm. 2023;15(1):274-9. doi: 10.22159/ijap.2023v15i1.46281.
21. Arwansyah A, Lewa AF, Muliani M, Warnasih S, Mustopa AZ, Arif AR. Molecular recognition of Moringa oleifera active compounds for stunted growth prevention using network pharmacology and molecular modeling approach. ACS Omega. 2023;8(46):44121-38. doi: 10.1021/acsomega.3c06379, PMID 38027368, PMCID PMC10666129.
22. Fitriana M, Mun’im A, Firdayani WA, Adikusuma W. Exploration of the active compounds of Moringa Oleifera lam as Hiv-1 reverse transcriptase inhibitor: a network pharmacology and molecular docking approach. Int J App Pharm. 2024;16(2):237-46. doi: 10.22159/ijap.2024v16i2.49855.
23. Zhang L, Wang P, Yang Z, Du F, Li Z, Wu C. Molecular dynamics simulation exploration of the interaction between curcumin and myosin combined with the results of spectroscopy techniques. Food Hydrocoll. 2020;101:105455. doi: 10.1016/j.foodhyd.2019.105455.
24. Wang Y, Xing M, Cao Q, Ji A, Liang H, Song S. Biological activities of fucoidan and the factors mediating its therapeutic effects: a review of recent studies. Mar Drugs. 2019;17(3):183. doi: 10.3390/md17030183, PMID 30897733, PMCID PMC6471298.
25. George AM, Chakraborty K, Paulose SK, Bose C, Dhara S. Anti-coagulant effects of α-(1 → 3)/(1 → 4) linked sulfated galactofucan from brown macroalga Sargassum plagiophyllum (C. Agardh) in human umbilical vein endothelial cells. Food Biosci. 2024;62:105467. doi: 10.1016/j.fbio.2024.105467.
26. Guo F, Yang R, Xiong X, Yuan Y, Zhang L, Hua C. Taxifolin inhibits platelet activation and thrombosis by regulating the PI3K/Akt and MAPK signaling pathways. Mol Nutr Food Res. 2025;69(16):e70129. doi: 10.1002/mnfr.70129, PMID 40635239.
27. Li J, Tao Q, Xie Y, Wang P, Jin R, Huang X. Exploring the targets and molecular mechanisms of thalidomide in the treatment of ulcerative colitis: network pharmacology and experimental validation. Curr Pharm Des. 2023;29(34):2721-37. doi: 10.2174/0113816128272502231101114727, PMID 37961863.
28. Zan X, Zhang S, Liu Q, Wang F, Tian M, Cao Y. Network pharmacology molecular docking and in vivo study on oleanolic acid against psoriasis. Front Med. 2025;12:1616886. doi: 10.3389/fmed.2025.1616886, PMID 41122516, PMCID PMC12535998.
29. De Kock L, Freson K. The (patho) biology of SRC kinase in platelets and megakaryocytes. Med (Kaunas Lith). 2020;56(12):633. doi: 10.3390/medicina56120633, PMID 33255186, PMCID PMC7759910.
30. Xu X, Dai Y, Zhu H, Zhang J, Li Y, Jiang H. Mitogen-activated protein kinase 1 regulates platelet function and thrombus formation. J Thromb Haemost. 2025;23(9):2944-57. doi: 10.1016/j.jtha.2025.05.022, PMID 40447106.
31. Maguire PB, Parsons ME, Szklanna PB, Zdanyte M, Münzer P, Chatterjee M. Comparative platelet releasate proteomic profiling of acute coronary syndrome versus stable coronary artery disease. Front Cardiovasc Med. 2020;7:101. doi: 10.3389/fcvm.2020.00101, PMID 32671099, PMCID PMC7328343.
32. Li Y, Luo L, Wu J, Wu Z, Jiang H, Chen Z. IL-1β induce CAR-T-associated coagulopathy via the Hsp90/kallikrein/uPA pathway. Blood. 2024;144(Suppl 1):1197. doi: 10.1182/blood-2024-202845.
33. Hardiningtyas SD, Jauharah N, Tarman K. Characteristics of bioactive components in fermented Sargassum and Ulva Seaweed using SCOBY as potential anti-diabetic candidates. BIO Web Conf. 2024;106:02013. doi: 10.1051/bioconf/202410602013.
34. Hidayati JR, Yudiati E, Pringgenies D, Arifin Z, Oktaviyanti DT. Antioxidant activities total phenolic compound and pigment contents of tropical Sargassum sp. extract macerated in different solvents polarity. J Kelautan Tropis. 2019;22(1):73-80. doi: 10.14710/jkt.v22i1.4404.
35. Tanna B, Mishra A. Nutraceutical potential of seaweed polysaccharides: structure, bioactivity safety and toxicity. Compr Rev Food Sci Food Saf. 2019;18(3):817-31. doi: 10.1111/1541-4337.12441, PMID 33336929.
36. Xiong Z, Yang H. Unraveling the pharmacological intricacies of Kurarinone in osteoporosis: insights from a network pharmacology approach. Pharmacogn Mag. 2024;20(4):1350-8. doi: 10.1177/09731296241259563.
37. Kampen S, Duy Vo D, Zhang X, Panel N, Yang Y, Jaiteh M. Structure-guided design of G-protein-coupled receptor polypharmacology. Angew Chem Int Ed Engl. 2021;60(33):18022-30. doi: 10.1002/anie.202101478, PMID 33904641, PMCID PMC8456950.
38. Mohan A, Rendine N, Mohammed MK, Jeeva A, Ji HF, Talluri VR. Structure-based virtual screening in silico docking ADME properties prediction and molecular dynamics studies for the identification of potential inhibitors against SARS-CoV-2 Mpro. Mol Divers. 2022;26(3):1645-61. doi: 10.1007/s11030-021-10298-0, PMID 34480682, PMCID PMC8417657.
39. Pavan M, Menin S, Bassani D, Sturlese M, Moro S. Qualitative estimation of protein-ligand complex stability through thermal titration molecular dynamics simulations. J Chem Inf Model. 2022;62(22):5715-28. doi: 10.1021/acs.jcim.2c00995, PMID 36315402, PMCID PMC9709921.
40. Nieto Fabregat F, Lenza MP, Marseglia A, Di Carluccio C, Molinaro A, Silipo A. Computational toolbox for the analysis of protein-glycan interactions. Beilstein J Org Chem. 2024;20:2084-107. doi: 10.3762/bjoc.20.180, PMID 39189002, PMCID PMC11346309.
41. Bosch FT, Nisio MD, Buller HR, Van Es N. Diagnostic and therapeutic management of upper extremity deep vein thrombosis. J Clin Med. 2020;9(7):2069. doi: 10.3390/jcm9072069, PMID 32630244, PMCID PMC7408847.
42. Kao TW, Chen ZW, Lin YH. Anticoagulation for patients with concomitant atrial fibrillation and end-stage renal disease: a systematic review and network meta-analysis. J Am Heart Assoc. 2024;13(8):e034176. doi: 10.1161/jaha.123.034176, PMID 38606775, PMCID PMC11262503.
43. Stanifer JW, Pokorney SD, Chertow GM, Hohnloser SH, Wojdyla DM, Garonzik S. Apixaban versus warfarin in patients with atrial fibrillation and advanced chronic kidney disease. Circulation. 2020;141(17):1384-92. doi: 10.1161/circulationaha.119.044059, PMID 32160801.
44. Manggau M, Kasim S, Fitri N, Aulia NS, Agustiani AN, Raihan M. Antioxidant anti-inflammatory and anticoagulant activities of sulfate polysaccharide isolate from brown alga Sargassum policystum. IOP Conf S Earth Environ Sci. 2022;967(1):012029. doi: 10.1088/1755-1315/967/1/012029.
45. Wu YW, Ta GH, Lung YC, Weng CF, Leong MK. In silico prediction of skin permeability using a two-QSAR approach. Pharmaceutics. 2022;14(5):961. doi: 10.3390/pharmaceutics14050961, PMID 35631545, PMCID PMC9143389.
Published
How to Cite
Issue
Section
Copyright (c) 2026 FRANCISCA DIANA ALEXANDRA, MARIANTI A. MANGGAU, MUH.NASSRUM MASSI, YANTI LEMAN, YSRAFIL YSRAFIL
This work is licensed under a Creative Commons Attribution 4.0 International License.